APCCC Diagnostics 2025: What Do You Want to Have Reported in MRI and PSMA PET?

EAU 2025: Matching-Adjusted Indirect Comparison between Enzalutamide and Darolutamide Doublet Therapy for mHSPC EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: Evidence for and ...

Physical Activity and Testicular Cancer Survivorship Health-Related Quality of Life: A Scoping Review - Beyond the Abstract ...

Robotic versus Open Cystectomy with Ileal Conduit for the Management of Neurogenic Bladder: A Comparative Study - Beyond the Abstract ...

Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...

Alicia Morgans sits down with Charles Ryan to discuss the recent publication of Urologic Oncology: Multidisciplinary Care for Patients, a book she co-edited with Kelly Stratton. Nicolas Mottet, MD, Ph ...

ASCO GU 2025: Case-Based Session: Failure of Immunotherapy in Renal Cell Cancer – What’s Next ASCO GU 2025: The Future of Biomarkers in Renal Cell Carcinoma ASCO GU 2025: Biomarkers in Renal Cell ...

WCE 2019: Ambulatory Percutaneous Nephrolithotomy in Free - Standing Surgery Center: Outcomes of the First 550 Cases WCE 2019: Investigating the Role of Smaller Tract Percutaneous Nephrolithotomy in ...

(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025, held in Lugano, Switzerland, on February 27 th and 28 th, was host to a session addressing the contemporary ...

Barcelona, Spain (UroToday.com) Rucaparib is a PARP inhibitor and has shown antitumor activity in patients with mCRPC and a deleterious DNA damage repair-deficient gene alteration. Initial results ...

Read the Full Video Transcript Alicia Morgans: Hi. I'm so excited to be here at ASCO GU 2024, where I am speaking with Dr. Alan Bryce, who is the Chief Clinical Officer of City of Hope, Arizona, which ...

ASCO 2024 Bladder Cancer ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options? ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive ...